These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21298986)

  • 1. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
    Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
    Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
    Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
    Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM;
    Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeting CD20 in rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
    Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
    J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
    Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Belmonte Serrano MA; Pincus T
    Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab for rheumatoid arthritis.
    Palylyk-Colwell E; McGahan L
    Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell therapies in established rheumatoid arthritis.
    Leandro MJ; Becerra-Fernandez E
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
    Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
    Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
    Ann Rheum Dis; 2012 Mar; 71(3):374-7. PubMed ID: 21972242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.